Abstract
Cerebrospinal fluid (CSF) levels of homovanillic acid (HVA), a major catabolite of dopamine, were substantially less in 21 patients with amyotrophic lateral sclerosis (ALS) than in 19 controls. There was also a significant reduction in the probenecid-induced accumulation of HVA in the CSF of ALS patients as compared with control subjects. Since probenecid inhibits the efflux of HVA from the central nervous system, the results suggest that central dopamine synthesis may be diminished in ALS. A therapeutic trial of levodopa, the immediate precursor of dopamine, in ten ALS patients failed to improve motor function. Defects in central dopamine metabolism, inferred from these tests applicable to the living patient, evidently may attend neurologic disorders which are unresponsive to precursor loading with levodopa.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
